{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:50:48Z","timestamp":1791204648271,"version":"4.2.0"},"reference-count":246,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973171"],"award-info":[{"award-number":["81973171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373710"],"award-info":[{"award-number":["82373710"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502986"],"award-info":[{"award-number":["81502986"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173652"],"award-info":[{"award-number":["82173652"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medicinal Research Reviews"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Wee kinases, including Wee1, Myt1 (PKMYT1) and Wee2, serve as critical regulators of the DNA damage response by inhibiting the G2\/M transition and have attracted increasing attention as a targetable vulnerability in TP53\u2010deficient cancers. Wee1 is the fastest progressing member in clinical research, and its inhibitors such as AZD\u20101775 and ZN\u2010c3 are under clinical evaluation. Because toxicity and resistance persist with existing agents, research is moving toward newer strategies such as protein degradation technologies. Proceeding from sequence and structure, we, for the first time, use chemoinformatics to delineate the chemical space of the Wee1 binding pocket and classify reported inhibitors into three pocket engagement types, thereby constructing a high\u2010resolution pocket map and an anchorable Markush for designing inhibitors with high selectivity and activity. We further summarize design principles for targeted degradation of Wee1 and outline combination strategies grounded in synthetic lethality, and we curate recent preclinical and ongoing clinical advances with discussion of biomarker\u2010guided enrollment and dosing schedules. By linking structural mechanisms to pharmacology and clinical placement, this review provides an actionable framework for next\u2010generation Wee1\u2010directed drug design and translation in oncology.<\/jats:p>","DOI":"10.1002\/med.70057","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:47:30Z","timestamp":1779770850000},"page":"1499-1542","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6143-2921","authenticated-orcid":false,"given":"Xin","family":"Xue","sequence":"first","affiliation":[{"name":"National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae Nanjing University of Chinese Medicine Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhai","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqi","family":"Bei","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanqiao","family":"Shi","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Pharmaceutical University Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6009-3208","authenticated-orcid":false,"given":"Yao","family":"Chen","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine Nanjing Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5793-6959","authenticated-orcid":false,"given":"Nianguang","family":"Li","sequence":"additional","affiliation":[{"name":"National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae Nanjing University of Chinese Medicine Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.610"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42764-022-00094-x"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.05.22"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes13061101"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123793"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1039\/C6MD00439C"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2013.13837"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00959-2"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(24)60694-1"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201800188"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.26062"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2537"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01458"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.997.997"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1474337"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1200466"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.2c00481"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01371-6"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c01558"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.3727\/096504020X15982623243955"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.06.006"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114786"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128973"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.07.015"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5233.86"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.110901"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01619"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.35.22300"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1298245"},{"issue":"57","key":"e_1_2_14_31_1","first-page":"e59","article-title":"Development and Characterization of a WEE1 Kinase Degrader. Cell","volume":"27","author":"Li Z.","year":"2020","journal-title":"Chemistry and Biology"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1915"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012716"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102531"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11020195"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2004.12.017"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113911"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.08.011"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.6.1.119"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038254"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.01.170"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00060-y"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.08.028"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.0.CO;2-5"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0118"},{"key":"e_1_2_14_46_1","first-page":"5259","article-title":"Pkmyt1 Aggravates The Progression of Ovarian Cancer by Targeting Sirt3","volume":"24","author":"Xuan Z. H.","year":"2020","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110814"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-2303"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51959-3"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2019-0022"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14110"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0587"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-2050-4"},{"key":"e_1_2_14_54_1","unstructured":"ClinicalTrials.gov.2025.WEE1 Inhibitor MK\u20101775 Docetaxel and Cisplatin Before Surgery in Treating Patients with Head and Neck Cancer (NCT02508246). accessed 25 Aug https:\/\/clinicaltrials.gov\/study\/NCT02508246."},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.74600"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2855394"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00790-9"},{"key":"e_1_2_14_58_1","first-page":"16","article-title":"Wee1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with P53 Mutations","author":"Ariyoshi M.","year":"2024","journal-title":"Cancers (Basel)"},{"key":"e_1_2_14_59_1","article-title":"Mir\u2010138\u20105P Inhibits the Growth and Invasion of Glioma Cells by Regulating Wee1","volume":"2022","author":"Gong J.","year":"2022","journal-title":"Anal Cell Pathol (Amst)"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1065-7"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-72"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.3727\/096504022X16493267465621"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144608"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep43517"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104233"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003049"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.03.003"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0571-2"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.17.2.571"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1270542"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0120"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.10.043"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161544"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S462056"},{"issue":"245","key":"e_1_2_14_75_1","first-page":"107","article-title":"Down\u2010Regulation of Sirt3 Promotes Ovarian Carcinoma Metastasis","volume":"475","author":"Dong X. C.","year":"2016","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-5511"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02821-5"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00223"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114606"},{"key":"e_1_2_14_80_1","first-page":"e01712","article-title":"J. Bodily, and L. A. Laimins, \u201cSuppression of Microrna 424 Levels by Human Papillomaviruses is Necessary for Differentiation\u2010Dependent Genome Amplification","volume":"24","author":"Hong S.","year":"2017","journal-title":"Journal of Virology 91"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13018"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.10.002"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S244550"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01522-y"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000545"},{"key":"e_1_2_14_86_1","unstructured":"Acrivon Therapeutics Announces Initiation of Phase 1 Trial for ACR\u20102316 a Dual WEE1\/PKMYT1 Inhibitor [https:\/\/cn.investing.com\/news\/company-news\/article-93CH-2511219]."},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01476"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-01021-z"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05527-y"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.629266"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02388-x"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11900"},{"issue":"20","key":"e_1_2_14_93_1","article-title":"Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets","volume":"25","author":"Khamidullina A. I.","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"1213","key":"e_1_2_14_94_1","first-page":"108","article-title":"Phase I Clinical Trial of the WEE1 Inhibitor Adavosertib (Azd1775) with Irinotecan in Children with Relapsed Solid Tumors: A Cog Phase I Consortium Report (Advl1312)","volume":"26","author":"Cole K. A.","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3865"},{"key":"e_1_2_14_96_1","first-page":"49","article-title":"Combination of Parp and WEE1 Inhibitors in Vitro: Potential for Use in the Treatment of Shh Medulloblastoma","author":"Lukoseviciute M.","year":"2023","journal-title":"Oncology Reports"},{"key":"e_1_2_14_97_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0463"},{"key":"e_1_2_14_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00763-7"},{"key":"e_1_2_14_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00730"},{"key":"e_1_2_14_100_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2580"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642328"},{"key":"e_1_2_14_102_1","article-title":"Dr Huffman on the Investigation of Azenosertib Plus Gemcitabine in Advanced Pancreatic Cancer","author":"Huffman B.","year":"2024","journal-title":"OncLive Commentary Video"},{"key":"e_1_2_14_103_1","unstructured":"D. F. C.Institute \u201cPhase 2 Single Arm Trial Testing the Azenosertib (Zn\u2010C3) WEE1 Inhibitor in Combination with Gemcitabine in Second\u2010Line Advanced Pancreatic Adenocarcinoma \u201dDana\u2010Farber Cancer Institute clinical trial.2023."},{"key":"e_1_2_14_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07180.x"},{"key":"e_1_2_14_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(22)00965-0"},{"key":"e_1_2_14_106_1","doi-asserted-by":"publisher","DOI":"10.1093\/biolre\/ioaa097"},{"key":"e_1_2_14_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.03.005"},{"key":"e_1_2_14_108_1","unstructured":"Medicine USNLo.2025. ClinicalTrials.gov.https:\/\/clinicaltrials.gov."},{"key":"e_1_2_14_109_1","unstructured":"E. M.Agency: European Union Clinical Trials Register.2025.https:\/\/www.clinicaltrialsregister.eu."},{"key":"e_1_2_14_110_1","unstructured":"C.Library: Cochrane Central Register of ControlledTrials (CENTRAL).https:\/\/www.cochranelibrary.com\/central.2025."},{"key":"e_1_2_14_111_1","unstructured":"Organization WH. WHO International Clinical Trials Registry Platform (ICTRP).https:\/\/trialsearch.who.int.2025."},{"key":"e_1_2_14_112_1","unstructured":"ClinicalTrials.gov.2025.Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS\u20108201a) and Azenosertib (ZN\u2010c3) in Patients with Stomach or Other Solid Tumors (NCT06364410). accessed 25 Aug https:\/\/clinicaltrials.gov\/study\/NCT06364410."},{"key":"e_1_2_14_113_1","unstructured":"ClinicalTrials.gov.Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or 109 HR+\/HER2\u2010 Advanced Breast Cancer (NCT06612203).2025. accessed 25 Aug https:\/\/clinicaltrials.gov\/study\/NCT06612203."},{"key":"e_1_2_14_114_1","unstructured":"ClinicalTrials.gov.Phase 1 Study of ACR\u20102316 in Specific Advanced Solid Tumors (NCT06667141). accessed 25 Aug https:\/\/clinicaltrials.gov\/study\/NCT06667141.2025."},{"key":"e_1_2_14_115_1","unstructured":"ClinicalTrials.gov.2025.A Study to Evaluate the Safety Tolerability and Efficacy of Escalating Doses of BMS\u2010986463 in Participants with Select Advanced Malignant Tumors (NCT06476808). accessed 25 Aug https:\/\/clinicaltrials.gov\/study\/NCT06476808."},{"key":"e_1_2_14_116_1","unstructured":"ClinicalTrials.gov.2025.Study of SGR\u20103515 in Participants with Advanced Solid Tumors (NCT06463340). accessed 25 Aug https:\/\/clinicaltrials.gov\/study\/NCT06463340."},{"key":"e_1_2_14_117_1","unstructured":"ClinicalTrials.gov.Study of APR\u20101051 in Patients with Advanced Solid Tumors (NCT06260514). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT06260514.2025."},{"key":"e_1_2_14_118_1","unstructured":"ClinicalTrials.gov.2025.A Biomarker Study of the WEE1 Inhibitor Azenosertib (ZN\u2010c3) in Women with Recurrent or Persistent Uterine Serous Carcinoma (NCT06369155). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT06369155."},{"key":"e_1_2_14_119_1","unstructured":"ClinicalTrials.gov.2025.A Study of ZN\u2010c3 Alone and in Combination with Anti\u2010PD1 in Participants with Locally Advanced or Metastatic Solid Tumors (NCT06015659). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT06015659."},{"key":"e_1_2_14_120_1","unstructured":"ClinicalTrials.gov.2025.Study of ZN\u2010c3 in People with Ovarian Cancer Who Have an SLFN11 Biomarker (NCT05765812). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT05765812."},{"key":"e_1_2_14_121_1","unstructured":"ClinicalTrials.gov.2025.Study of ZN\u2010c3 in Combination with Enfortumab Vedotin in People with Metastatic Urothelial Cancer (mUC) (NCT05815160). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT05815160."},{"key":"e_1_2_14_122_1","unstructured":"ClinicalTrials.gov.2025.ZN\u2010c3 in Adult Participants with Metastatic Colorectal Cancer (With Encorafenib + Cetuximab) (NCT05743036). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT05743036."},{"key":"e_1_2_14_123_1","unstructured":"ClinicalTrials.gov. Study of ZN\u2010c3 and Niraparib in Participants with Advanced Ovarian Cancer (NCT05682170). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT05682170."},{"key":"e_1_2_14_124_1","unstructured":"ClinicalTrials.gov.2025.A Study of Azenosertib (ZN\u2010c3) in Subjects with Platinum\u2010Resistant High\u2010Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (DENALI) (NCT05128825). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT05128825."},{"key":"e_1_2_14_125_1","unstructured":"ClinicalTrials.gov.A Phase 1\/2 Open\u2010Label Study to Evaluate ZN\u2010c3 Alone and in Combination with Bevacizumab in People with Solid Tumors (NCT05198804). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT05198804.2025."},{"key":"e_1_2_14_126_1","unstructured":"ClinicalTrials.gov.2025.Study of ZN\u2010c3 + Gemcitabine in Platinum\u2010Resistant High\u2010Grade Serous Ovarian Cancer (NCT05109975). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT05109975."},{"key":"e_1_2_14_127_1","unstructured":"ClinicalTrials.gov.A Study of ZN\u2010c3 in Women with Recurrent or Persistent Uterine Serous Carcinoma (NCT04814108). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT04814108."},{"key":"e_1_2_14_128_1","unstructured":"ClinicalTrials.gov.2025.Study of SY\u20104835 in People with Advanced Solid Tumors (NCT05291182). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT05291182."},{"key":"e_1_2_14_129_1","unstructured":"ClinicalTrials.gov.2025.Testing the Addition of an Anti\u2010cancer Drug Adavosertib to Radiation for Esophageal or Gastroesophageal Junction Cancer (NCT04460937). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT04460937."},{"key":"e_1_2_14_130_1","unstructured":"ClinicalTrials.gov.The Safety and Pharmacokinetics and Preliminary Efficacy of IMP7068 in Patients with Advanced Solid Tumors (NCT04768868).https:\/\/clinicaltrials.gov\/study\/NCT04768868.110Accessed 25 Aug2025."},{"key":"e_1_2_14_131_1","unstructured":"ClinicalTrials.gov.2025.Study of Oral Debio 0123 in Combination with Carboplatin in Participants with Advanced Solid Tumors (NCT03968653). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03968653."},{"key":"e_1_2_14_132_1","unstructured":"ClinicalTrials.gov.AZD1775 in Advanced Acute Myeloid Leukemia Myelodysplastic Syndrome and Myelofibrosis (NCT03718143). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03718143.2025."},{"key":"e_1_2_14_133_1","unstructured":"ClinicalTrials.gov.Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03284385.2025."},{"key":"e_1_2_14_134_1","unstructured":"ClinicalTrials.gov.AZD1775 in Treating Patients with Advanced Refractory Solid Tumors with CCNE1 Amplification (NCT03253679). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03253679.2025."},{"key":"e_1_2_14_135_1","unstructured":"ClinicalTrials.gov.2025.AZD1775 in Women with Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma (NCT03668340). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03668340."},{"key":"e_1_2_14_136_1","unstructured":"ClinicalTrials.gov.2025.Testing AZD1775 in Combination with Radiotherapy and Chemotherapy in Cervical Upper Vaginal and Uterine Cancers (NCT03345784). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03345784."},{"key":"e_1_2_14_137_1","unstructured":"ClinicalTrials.gov.2025.Effect of Food on the Pharmacokinetics of the WEE1 Inhibitor AZD1775 (Adavosertib) (NCT03315091). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03315091."},{"key":"e_1_2_14_138_1","unstructured":"ClinicalTrials.gov.2025.WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer (WISTERIA) (NCT03028766). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03028766."},{"key":"e_1_2_14_139_1","unstructured":"ClinicalTrials.gov.WEE1 Inhibitor AZD1775 with or Without Cytarabine in Treating Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02666950). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT02666950.2025."},{"key":"e_1_2_14_140_1","unstructured":"ClinicalTrials.gov.2025.A Phase II Study of Cisplatin + AZD1775 in Metastatic Triple\u2010negative Breast Cancer and Evaluation of pCDC2 as a Biomarker of Target Response (NCT03012477). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT03012477."},{"key":"e_1_2_14_141_1","unstructured":"ClinicalTrials.gov.2025.A Phase II Open\u2010Label Multi\u2010Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients with Platinum Refractory Extensive\u2010Stage Small\u2010Cell Lung Cancer (BALTIC) (NCT02937818). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT02937818."},{"key":"e_1_2_14_142_1","unstructured":"ClinicalTrials.gov.2025.Study of Irinotecan and AZD1775 a Selective WEE1 Inhibitor in RAS or BRAF Mutated Second\u2010line Metastatic Colorectal Cancer (NCT02906059). Accessed 25 Aug.https:\/\/clinicaltrials.gov\/study\/NCT02906059."},{"key":"e_1_2_14_143_1","unstructured":"ClinicalTrials.gov. Adavosertib Before Surgery in Treating Patients with Advanced High\u2010Grade Ovarian Fallopian Tube or Primary Peritoneal Cancer (NCT02659241). Accessed 25 Aug 2025.https:\/\/clinicaltrials.gov\/study\/NCT02659241."},{"key":"e_1_2_14_144_1","unstructured":"ClinicalTrials.gov. Phase Ib Study to Determine the Maximum Tolerated Dose of AZD1775 Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumours (NCT02610075). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02610075."},{"key":"e_1_2_14_145_1","unstructured":"ClinicalTrials.gov. Phase II Single\u2010arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients (NCT02593019). Accessed 25 Aug2025. 111.https:\/\/clinicaltrials.gov\/study\/NCT02593019."},{"key":"e_1_2_14_146_1","unstructured":"ClinicalTrials.gov. OLAParib COmbinations (OLAPCO) (NCT02576444). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02576444."},{"key":"e_1_2_14_147_1","unstructured":"ClinicalTrials.gov. Adavosertib Plus Chemotherapy in Platinum\u2010Sensitive High\u2010Grade Serous Ovarian Cancer (NCT02272790). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02272790."},{"key":"e_1_2_14_148_1","unstructured":"ClinicalTrials.gov. \u201cPhase Ib Study of AZD1775 in Combination with Carboplatin and Paclitaxel in Adult Asian Patients with Solid Tumours (NCT02341456). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02341456."},{"key":"e_1_2_14_149_1","unstructured":"ClinicalTrials.gov. Nab\u2010Paclitaxel and Gemcitabine with or Without WEE1 Inhibitor AZD1775 in Treating Patients with Metastatic Pancreatic Cancer (NCT02194829). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02194829."},{"key":"e_1_2_14_150_1","unstructured":"ClinicalTrials.gov. A Phase 0 Study of AZD1775 in Recurrent GBM Patients (NCT02207010). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02207010."},{"key":"e_1_2_14_151_1","unstructured":"ClinicalTrials.gov. Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors (NCT02095132). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02095132."},{"key":"e_1_2_14_152_1","unstructured":"ClinicalTrials.gov. Cisplatin with or Without WEE1 Inhibitor MK\u20101775 in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT02196168). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02196168."},{"key":"e_1_2_14_153_1","unstructured":"ClinicalTrials.gov. Dose Escalation Trial of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Gemcitabine and Radiation for Patients with Locally Advanced Pancreatic Cancer (NCT02037230). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT02037230."},{"key":"e_1_2_14_154_1","unstructured":"ClinicalTrials.gov. Molecular Profiling\u2010Based Assignment of Cancer Therapy (NCI\u2010MPACT) (NCT01827384). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT01827384."},{"key":"e_1_2_14_155_1","unstructured":"ClinicalTrials.gov. AZD1775 for Advanced Solid Tumors (NCT01748825). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT01748825."},{"key":"e_1_2_14_156_1","unstructured":"ClinicalTrials.gov. A Study of Adavosertib (MK\u20101775) in Combination with Topotecan\/Cisplatin in Participants with Cervical Cancer (MK\u20101775\u2010008) (NCT01076400). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT01076400."},{"key":"e_1_2_14_157_1","unstructured":"ClinicalTrials.gov. A Dose Escalation Study of Adavosertib (MK\u20101775) as Monotherapy and in Combination with 5\u2010FU or 5\u2010FU\/CDDP in Patients with Advanced Solid Tumors (NCT01047007). Accessed 25 Aug2025.https:\/\/clinicaltrials.gov\/study\/NCT01047007."},{"key":"e_1_2_14_158_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes14071346"},{"key":"e_1_2_14_159_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1488359"},{"key":"e_1_2_14_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100394"},{"key":"e_1_2_14_161_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-12-45"},{"key":"e_1_2_14_162_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0650"},{"key":"e_1_2_14_163_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.971959"},{"key":"e_1_2_14_164_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.954430"},{"key":"e_1_2_14_165_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3348"},{"key":"e_1_2_14_166_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0213"},{"key":"e_1_2_14_167_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33048"},{"key":"e_1_2_14_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32554-X"},{"key":"e_1_2_14_169_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5541"},{"key":"e_1_2_14_170_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03167"},{"key":"e_1_2_14_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.180"},{"key":"e_1_2_14_172_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754524"},{"key":"e_1_2_14_173_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28098"},{"key":"e_1_2_14_174_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-012-6440-6"},{"key":"e_1_2_14_175_1","article-title":"Azenosertib Shows Promising Efficacy in Platinum\u2010Resistant Ovarian Cancer","author":"Sava J.","year":"2025","journal-title":"Targeted Oncology"},{"key":"e_1_2_14_176_1","article-title":"Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum\u2010Resistant Ovarian Cancer","author":"Doherty K.","year":"2025","journal-title":"OncLive"},{"key":"e_1_2_14_177_1","first-page":"113","article-title":"Partial Clinical Holds on 3 Trials Evaluating Azenosertib in Advanced Solid Tumors","author":"Ryan C.","year":"2024","journal-title":"OncLive"},{"key":"e_1_2_14_178_1","unstructured":"Sponsor: K\u2010Group B. Inc.: ZN\u2010c3 in Adult Participants with Metastatic Colorectal Cancer. K\u2010Group Beta Inc. (subsidiary of Zentalis Pharmaceuticals Inc.);2025."},{"key":"e_1_2_14_179_1","unstructured":"M.Filipa Lynce \u201cZap\u2010It: Zn\u2010C3 + Carboplatin + Pembrolizumab in Mtnbc \u201dDana\u2010Farber Cancer Institute;2024."},{"key":"e_1_2_14_180_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-1194"},{"key":"e_1_2_14_181_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00147"},{"key":"e_1_2_14_182_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02434"},{"key":"e_1_2_14_183_1","doi-asserted-by":"publisher","DOI":"10.1080\/01677063.2021.1928663"},{"key":"e_1_2_14_184_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2443.2000.00367.x"},{"key":"e_1_2_14_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112524"},{"key":"e_1_2_14_186_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-021-02285-z"},{"key":"e_1_2_14_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdev.2021.203754"},{"key":"e_1_2_14_188_1","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.329"},{"key":"e_1_2_14_189_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2225106"},{"key":"e_1_2_14_190_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1823882"},{"key":"e_1_2_14_191_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901443h"},{"key":"e_1_2_14_192_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2012.06.007"},{"key":"e_1_2_14_193_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku316"},{"key":"e_1_2_14_194_1","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.109.081984"},{"key":"e_1_2_14_195_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23071818"},{"key":"e_1_2_14_196_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0512591"},{"key":"e_1_2_14_197_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01121"},{"key":"e_1_2_14_198_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004203"},{"key":"e_1_2_14_199_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.4c06127"},{"key":"e_1_2_14_200_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901241e"},{"key":"e_1_2_14_201_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2011.05.067"},{"key":"e_1_2_14_202_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0875"},{"key":"e_1_2_14_203_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15637"},{"key":"e_1_2_14_204_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-4423"},{"key":"e_1_2_14_205_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-6185"},{"key":"e_1_2_14_206_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e15052"},{"key":"e_1_2_14_207_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-C147"},{"key":"e_1_2_14_208_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-1977"},{"key":"e_1_2_14_209_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10231"},{"key":"e_1_2_14_210_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-6177"},{"key":"e_1_2_14_211_1","first-page":"11","article-title":"Wee1 Rather Than Plk1 Is Inhibited by Azd1775 at Therapeutically Relevant Concentrations","author":"Serpico A. F.","year":"2019","journal-title":"Cancers (Basel)"},{"key":"e_1_2_14_212_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4009"},{"issue":"4371","key":"e_1_2_14_213_1","first-page":"115","article-title":"Phase I Study Evaluating WEE1 Inhibitor Azd1775 as Monotherapy and in Combination with Gemcitabine, Cisplatin, or Carboplatin in Patients with Advanced Solid Tumors","volume":"34","author":"Leijen S.","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_14_214_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.222"},{"key":"e_1_2_14_215_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml5002745"},{"key":"e_1_2_14_216_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2007.07.016"},{"key":"e_1_2_14_217_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.3.6.899"},{"key":"e_1_2_14_218_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01098-8"},{"key":"e_1_2_14_219_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0025"},{"key":"e_1_2_14_220_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04638-9"},{"key":"e_1_2_14_221_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07835-2"},{"key":"e_1_2_14_222_1","article-title":"Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update","author":"Business Wire","year":"2025","journal-title":"Business Wire"},{"key":"e_1_2_14_223_1","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcad029"},{"key":"e_1_2_14_224_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1511700"},{"key":"e_1_2_14_225_1","first-page":"22","article-title":"Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy","author":"Esposito F.","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_14_226_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02096"},{"key":"e_1_2_14_227_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15033403"},{"key":"e_1_2_14_228_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00112-0"},{"key":"e_1_2_14_229_1","doi-asserted-by":"crossref","unstructured":"R. B.Tjeerdsma T. F.Ng M.Roorda et al.:WEE1 inhibitors trigger GCN2\u2010mediated activation of the integrated stress response.2025.","DOI":"10.1101\/2025.03.12.642754"},{"key":"e_1_2_14_230_1","article-title":"Structure of Cul2\u2013Vcb\u2013Protac\u2013Wee1 Complex at 3.6 \u00c5 Resolution","author":"Wang P.","year":"2024","journal-title":"Protein Data Bank (PDB): 8WDK"},{"key":"e_1_2_14_231_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128636"},{"key":"e_1_2_14_232_1","unstructured":"L.He F.Huang W.Xing et al.: WEE1 degrading compounds. pp. WO2024146502A: Beijing Neox Biotech Limited;2024."},{"key":"e_1_2_14_233_1","unstructured":"L.Fu L.Kong andZ.Qi: WEE1 protein kinase degrading agent and use thereof. pp. WO2024098692A: Hangzhou 116 Gerber Biomedicine Co. Ltd.;2024."},{"key":"e_1_2_14_234_1","unstructured":"J.Diao M.Chen W.Lai et al.: \u201cWee1 Degrading Compounds \u201dWO2023193789A1: Beijing Neox Biotech Ltd;2023."},{"key":"e_1_2_14_235_1","unstructured":"L.Fu L.Kong G.Lu Y.Xia andC.\u2010cLu: WEE1 protein kinase degradation agent and use thereof. WO2023083194A1;2023."},{"key":"e_1_2_14_236_1","unstructured":"J.Li W.L\u00fc D.Xiao et al.: WEE1 Protein Degraders. China: Chinese Academy of Sciences Shanghai Institute of Materia Medica. CN113402520A;2021."},{"key":"e_1_2_14_237_1","unstructured":"J.Sapienza J. R.Riggs J. T.Edwards D. K.Cashion andM. O.Pierce:Wee1 degrading compounds and uses thereof. WO2024006881A1;2024."},{"key":"e_1_2_14_238_1","unstructured":"S.Chen Y.Luo M.Lei B.Peng Y.Xu andY.Cang: Fused cyclic compound capable of degrading protein and use thereof. WO2021047627A1;2021."},{"key":"e_1_2_14_239_1","first-page":"12","article-title":"Targeted Protein Degradation: Principles and Applications of the Proteasome","author":"Kim Y.","year":"2023","journal-title":"Cells"},{"key":"e_1_2_14_240_1","first-page":"13","article-title":"Inhibitors, Protacs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin\u2010Dependent Kinase","author":"Rana S.","year":"2021","journal-title":"Cancers (Basel)"},{"key":"e_1_2_14_241_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-023-10606-w"},{"key":"e_1_2_14_242_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.11.001"},{"key":"e_1_2_14_243_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117683"},{"key":"e_1_2_14_244_1","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvac041"},{"key":"e_1_2_14_245_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.2c00245"},{"key":"e_1_2_14_246_1","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002718"},{"key":"e_1_2_14_247_1","first-page":"11","article-title":"Discovery and Preclinical Evaluation of Novel Oral WEE1 Degraders","author":"Xing W.","year":"2023","journal-title":"Proceedings of the AACR\u2010NCI\u2010EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. AACR"}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.70057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/med.70057","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.70057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:52:33Z","timestamp":1791201153000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.70057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":246,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1002\/med.70057"],"URL":"https:\/\/doi.org\/10.1002\/med.70057","archive":["Portico"],"relation":{},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2025-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}